Lv2
130 积分 2022-08-01 加入
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
5个月前
已完结
Nonclinical Efficacy and Toxicity and Selection of a Safe Clinical Starting Dose for an NMT Inhibitor in Development for Hematological Malignancies
7个月前
已关闭
Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice
7个月前
已完结
Design, Synthesis, In Vitro and In Vivo Evaluation of Cereblon Binding Bruton’s Tyrosine Kinase (BTK) Degrader CD79b targeted Antibody Drug Conjugates
8个月前
已完结
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
8个月前
已完结
DX‐8951f: Summary of Phase I Clinical Trials
8个月前
已完结
Preclinical and Clinical Development of Exatecan (DX-951f)
8个月前
已完结
皖公网安备34019202002308
